echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Expert Opin Investig Drugs: Disease Improvement in Ankylosing Spondylitis Treated with TNF Inhibitors

    Expert Opin Investig Drugs: Disease Improvement in Ankylosing Spondylitis Treated with TNF Inhibitors

    • Last Update: 2022-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    According to ASAS/EULAR recommendations, non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for AS; however, some patients may not respond adequately and others require continuous use to avoid symptoms; considering potential NSAID-related risks and/or side effects, which are not always possible


    Infliximab is a human/mouse (75% and 24%, respectively) IgG1K allotype-neutralizing monoclonal chimeric antibody with specificity and high affinity for human tumor necrosis factor-alpha


    Etanercept is a dimeric fusion protein of human TNF receptor linked to the Fc portion of human IgG1 [31]



    Source: Garcia-Montoya L, Emery P, Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.


    Garcia-Montoya L, Emery P, Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.
    Expert Opin Investig Drugs 2021 Nov;30(11)

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.